• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Relay Therapeutics Inc.

    2/26/25 4:30:45 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email
    S-8 1 rlay-20250226.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 26, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    Relay Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    47-3923475

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    399 Binney Street, 2nd Floor

    Cambridge, MA 02142

    (617) 370-8837

    (Address of Principal Executive Offices)

    Relay Therapeutics, Inc. 2020 Stock Option and Incentive Plan

    Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan

    (Full Title of the Plans)

    Sanjiv K. Patel

    President and Chief Executive Officer

    Relay Therapeutics, Inc.

    399 Binney Street, 2nd Floor

    Cambridge, MA 02142

    (617) 370-8837

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    William Collins, Esq.

    Gabriela Morales-Rivera, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

     

     

     

     

     

    Large accelerated filer

     

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

     

    ☐

    Smaller reporting company

    ☐

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    This Registration Statement on Form S-8 is being filed for the purpose of registering (i) an additional 8,387,785 shares of common stock, par value $0.001 per share (“Common Stock”) of Relay Therapeutics, Inc. (the “Registrant”) to be issued under the Registrant’s 2020 Stock Option and Incentive Plan, as amended (the “2020 Plan”) and (ii) an additional 1,677,557 shares of Common Stock of the Registrant to be issued under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”), for which Registration Statements on Form S-8 relating to the same employee benefit plans are effective.

    Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on July 17, 2020 (File No. 333-239912), March 25, 2021 (File No. 333-254704), February 24, 2022 (File No. 333-262974), February 23, 2023 (File No. 333-269959) and February 22, 2024 (File No. 333-277278) related to the 2020 Plan and the 2020 ESPP are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.

     


     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

    EXHIBIT INDEX

     

     

     

     

    Exhibit
    No.

     

    Description

     

     

    4.1

     

    Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 10-K (File No. 001-39385) filed on February 23, 2023).

     

     

    4.2

     

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 8-K (File No. 001-39385) filed on July 21, 2020).

     

     

    4.3

     

    Specimen stock certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).

     

     

    4.4

     

    Description of Securities (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-39385) filed on February 22, 2024).

     

     

    5.1*

     

    Opinion of Goodwin Procter LLP

     

     

    23.1*

     

    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

     

     

    23.2*

     

    Consent of Goodwin Procter LLP (included in Exhibit 5.1)

     

     

    24.1*

     

    Power of Attorney (included on signature page)

     

     

    99.1

     

    2020 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Form 10-K (File No. 001-39385) filed on February 24, 2022).

     

     

    99.2

     

    2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).

     

     

     

    107*

     

    Filing Fee Table

     

    *

    Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on the 26th day of February, 2025.

     

     

     

    RELAY THERAPEUTICS, INC.

     

     

    By:

     

    /s/ Sanjiv K. Patel

     

     

    Sanjiv K. Patel, M.D.

     

     

    President and Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Sanjiv K. Patel, M.D. and Brian Adams as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Name

     

    Title

     

    Date

     

     

     

     

     

    /s/ Sanjiv K. Patel

     

    President, Chief Executive Officer and Director

     

    February 26, 2025

    Sanjiv K. Patel, M.D.

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Thomas Catinazzo

     

    Chief Financial Officer

     

    February 26, 2025

    Thomas Catinazzo

     

    (Principal Accounting Officer and

    Principal Financial Officer)

     

     

     

     

     

     

     

    /s/ Alexis Borisy

     

    Director

     

    February 26, 2025

    Alexis Borisy

     

     

     

     

     

     

     

     

     

    /s/ Linda A. Hill

     

    Director

     

    February 26, 2025

    Linda A. Hill, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Douglas S. Ingram

     

    Director

     

    February 26, 2025

    Douglas S. Ingram

     

     

     

     

     

     

     

     

     

    /s/ Sekar Kathiresan

     

    Director

     

    February 26, 2025

    Sekar Kathiresan, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Mark Murcko

     

    Director

     

    February 26, 2025

    Mark Murcko, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Jami Rubin

     

    Director

     

    February 26, 2025

    Jami Rubin

     

     

     

     

     

     

     

     

     

    /s/ Laura Shawver

     

    Director

     

    February 26, 2025

    Laura Shawver, Ph.D.

     

     

     

     

     

     

     

     

     

     

     


    Get the next $RLAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    9/4/2025$15.00Buy
    Guggenheim
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $207B Market Shift: The Race for Fast Track Approval in Oncology

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ:ONCY), Relay Therapeutics (NASDAQ:RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ:

    2/5/26 9:35:00 AM ET
    $AVBP
    $ONCY
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

    CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be availa

    2/4/26 4:05:00 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

    Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough

    2/3/26 7:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    SEC Filings

    View All

    Relay Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    2/3/26 7:10:25 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Relay Therapeutics Inc.

    10-Q - Relay Therapeutics, Inc. (0001812364) (Filer)

    11/6/25 4:18:13 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

    11/6/25 4:12:33 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, R&D Bergstrom Donald A sold $166,677 worth of shares (21,581 units at $7.72), decreasing direct ownership by 5% to 420,047 units (SEC Form 4)

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    1/29/26 4:22:47 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Rahmer Peter was granted 994 shares and sold $100,473 worth of shares (13,038 units at $7.71), decreasing direct ownership by 18% to 276,610 units (SEC Form 4)

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    1/29/26 4:22:30 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Catinazzo Thomas sold $119,631 worth of shares (15,515 units at $7.71), decreasing direct ownership by 6% to 249,301 units (SEC Form 4)

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    1/29/26 4:20:25 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $13.00

    12/12/25 8:37:26 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Relay Therapeutics with a new price target

    Guggenheim resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $15.00

    9/4/25 9:07:32 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    11/14/24 1:22:38 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

    SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 4:20:24 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Relay Therapeutics Inc.

    SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

    2/14/24 10:03:03 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Financials

    Live finance-specific insights

    View All

    Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

    New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe

    12/11/24 6:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

    CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C

    12/9/24 4:05:30 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

    9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,

    9/9/24 6:55:20 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    View All

    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    6/11/25 4:05:00 PM ET
    $BCAX
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Section 32 Raises $740 Million Venture Fund

    SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

    11/4/21 8:14:00 AM ET
    $COIN
    $CRWD
    $EXAS
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology

    Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

    Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

    10/14/21 8:00:00 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care